www.fdanews.com/articles/159852-teva-okd-to-begin-phase-iii-chronic-heart-failure-trial-using-mesoblasts-cells

Teva OK’d to Begin Phase III Chronic Heart Failure Trial Using Mesoblast’s Cells

November 4, 2013

Teva and its partner Mesoblast have received notice of FDA approval for a Phase III trial of patients with congestive heart failure using Mesoblast’s Mesenchymal Precursor Cells.
Pharmabiz.com